Transgene to Participate in HTID Conference and Investor Access Forum in Paris
September 05 2024 - 11:45AM
UK Regulatory
Transgene to Participate in HTID Conference and Investor Access
Forum in Paris
Strasbourg, France, September
5, 2024, 5 : 45 PM CET – Transgene (Euronext
Paris: TNG), a biotech company that designs and develops
virus-based immunotherapies for the treatment of cancer, announces
that its management will participate in the following
upcoming investor meetings taking place in Paris,
France:
- 6th HealthTech Innovation Days (HTID),
September 17 & 18, 2024
- Investor Access Forum, October 15 & 16,
2024
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells.
The Company’s clinical-stage programs consist of a portfolio of
therapeutic vaccines and oncolytic viruses:
TG4050, the first individualized therapeutic vaccine based on
the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic
viruses based on the Invir.IO® viral backbone.
With Transgene’s myvac® platform, therapeutic vaccination
enters the field of precision medicine with a novel immunotherapy
that is fully tailored to each individual. The myvac® approach
allows the generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO®, Transgene is building
on its viral vector engineering expertise to design a new
generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at:
www.transgene.fr
Follow us on social media: X (previously-Twitter):
@Transgene - LinkedIn:
@Transgene
Contacts
Transgene Contact:
Transgene
Media Contact:
Media:
MEDiSTRAVA
Caroline Tosch
Frazer Hall/Sylvie Berrebi
Corporate Communication Manager
+ 44
(0)203 928 6900
+33 (0)3 68 33 27 38
transgene@medistrava.com
communication@transgene.fr
Lucie
Larguier
Chief Financial
Officer
Nadege
Bartoli
IR Analyst and Financial Communications
Officer
+33 (0)3 88 27 91 03
/00
investorrelations@transgene.fr
Transgene disclaimer
This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
- 20240905_Transgene-Upcoming-Investor-Events_EN
Transgene (LSE:0OCQ)
Historical Stock Chart
From Sep 2024 to Oct 2024
Transgene (LSE:0OCQ)
Historical Stock Chart
From Oct 2023 to Oct 2024